BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  NodThera Snags $40 Million in Financing to Target Diseases Driven by Chronic Inflammation

  Nodthera, a U.K.-based startup, snagged $40 million (£28 million) in Series A funding.

  June 25, 2018

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Licensing Deals Struck for Liver Disease and IBD Treatments

  This morning two companies announced deals that will yield potential benefits to multiple patient populations.

  June 25, 2018

   · 

  2 min read

   · 

  Alex Keown
• 

  Bio NC

  Biotechnology and the Environment: Can Biotech Save the Planet?

  Think biotechnology, you probably think cutting-edge development of drugs to treat diseases. Yet in 2007, a U.S. EPA report noted that industrial biotechnology and biobased manufacturing are more efficient, cleaner and make better use of sustainable renewable resources.

  June 25, 2018

   · 

  4 min read

   · 

  Mark Terry
• 

  BioMidwest

  Akero Therapeutics Launches with $65 Million Series A to Battle NASH

  Akero Therapeutics, headquartered in Cambridge, Massachusetts, closed on a $65 million Series A financing round.

  June 25, 2018

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  3 Clinical Trials with Mixed to Disastrous Results: Sophiris, Merrimack and Pfizer

  Although it’s great to report on successful clinical trial results, the reality is that only about one in 10 drugs make it to approval. With that number in mind, here are a couple companies reporting problematic clinical trials today.

  June 25, 2018

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  AbbVie, Calibr Collaborate to Develop Next-Generation CAR-T Therapies for Solid Tumors

  AbbVie is taking another shot at solid tumor treatments through a collaboration with Calibr.

  June 25, 2018

   · 

  2 min read

   · 

  Alex Keown
• 

  Pharm Country

  FDA Accepts Merck’s Supplemental Application for Keytruda in Advanced Melanoma

  The U.S. Food and Drug Administration (FDA) accepted Merck’s new supplemental Biologics License Application (sBLA) for Keytruda.

  June 25, 2018

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Roche’s Tecentriq Scores More Support for Lung Cancer Cocktail

  Roche announced that its Phase III IMpower 133 clinical trial of Tecentriq (atezolizumab) plus carboplatin and etoposide chemotherapy met its co-primary endpoints.

  June 25, 2018

   · 

  2 min read

   · 

  Mark Terry
• 

  Genetown

  Reconstitution of Russell Indexes Captures Six Biotech Companies

  Six biotechs will end the month of June as new additions to the Russell Indexes. Approximately $9 trillion in assets are benchmarked against Russell U.S. Indexes, which are reconstituted annually.

  June 25, 2018

   · 

  3 min read

   · 

  Alex Keown
• 

  FDA

  Cannabis-Based Drug Developers Are Hopeful as FDA Approves First Marijuana-based Seizure Treatment

  In a first of its kind ruling, the U.S. Food and Drug Administration approved GW Pharmaceuticals’ Epidiolex, a cannabis-based treatment for seizures associated with two rare forms of epilepsy, Lennox-Gastaut syndrome (LGS) and Dravet syndrome.

  June 25, 2018

   · 

  4 min read

   · 

  Alex Keown